Project Grant R01AR084311
Award Date
4/10/25
Completion Date
3/31/30
Dollars Obligated
$674K
Similar Awards
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $550,909 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Pittsburgh. This 5-year award, effective July 20, 2024 through June 30, 2029, supports research to understand the intrinsic and extrinsic factors regulating the development and persistence of skin-resident memory CD8 T cells. The research aims to elucidate how T cell...
This $1,672,816 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research at the University of Michigan to investigate how keratinocyte-derived signals regulate inflammation and innate immune responses in skin. The 5-year project aims to: 1) compare the spatiotemporal patterns of immune cell infiltration and protein kinase C activity in...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $295,294 to Biotherapeutics, Inc. for the development of a novel first-in-class topical immunoregulatory therapeutic for the treatment of plaque psoriasis. The key objectives are to: 1) evaluate the permeability and long-term stability of the topical drug product formulation, 2) compare...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $239,488 to the University of California, Davis to characterize the inflammatory pathologies underlying axial psoriatic arthritis (AxPsA) using total-body PET/CT imaging. The research aims to derive consolidated, whole-spine measures from this advanced imaging technology as...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $172,700 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to the University of California, Irvine. The grant supports the development and characterization of engineered recombinant cell-penetrating botulinum protease light chain variants. These engineered proteases aim to selectively cleave SNARE proteins in sensory neurons and immune cells, thereby regulating...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $401,433 from September 2023 to August 2025 to support research at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The research aims to investigate the role of protein O-GlcNAcylation in regulating keratinocyte function and its impact on skin...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $185,250 to the Molecular Medicine Research Institute in Sunnyvale, CA. The funding supports research to understand the role of fatty acid synthesis in regulating immune cell activation and metabolism during skin inflammation. Specifically, the project will generate cell-specific knockouts to study how inhibiting the fatty acid synthase...
This federal Project Grant award of $465,008, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to study whether remote characterization of gene/module expression can identify distinctive dynamics in blood transcriptional trajectories following treatment with biologics in early psoriatic arthritis (PsA). The award to New York University School of Medicine...
This SBIR Phase I award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to develop a novel topical therapeutic for the treatment of psoriasis. The key objectives are to: 1) characterize the therapeutic efficacy of the new treatment in a mouse model of psoriasis, 2) develop a topical drug product formulation and test its...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $176,148 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the role of PI16-expressing fibroblasts in mouse and human fibrosing skin disease. The 5-year research project aims to elucidate how this specific fibroblast subset responds to and...